Application of macrolide compound or salt thereof and pharmaceutical composition containing macrolide compound or salt

A macrolide and composition technology, which is applied in the field of the application of macrolide compounds or their salts and pharmaceutical compositions containing them, and can solve the problems of increased drug resistance and increased proportion of Streptococcus pneumoniae.

Active Publication Date: 2015-02-11
SHANGHAI INST OF PHARMA IND +1
View PDF7 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] 2. Acquired drug resistance
However, with the widespread use of second-generation erythromycin derivatives, the resistance of St

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of macrolide compound or salt thereof and pharmaceutical composition containing macrolide compound or salt
  • Application of macrolide compound or salt thereof and pharmaceutical composition containing macrolide compound or salt
  • Application of macrolide compound or salt thereof and pharmaceutical composition containing macrolide compound or salt

Examples

Experimental program
Comparison scheme
Effect test
No Example Login to view more

PUM

PropertyMeasurementUnit
Mic valueaaaaaaaaaa
Login to view more

Abstract

The invention discloses an application of a macrolide compound or a salt thereof and a pharmaceutical composition containing the macrolide compound or the salt, and provides a pharmaceutical composition. The pharmaceutical composition comprises one or more of a macrolide compound as shown in a formula 1 in the specification, a macrolide compound as shown in a formula 1' in the specification and pharmaceutically acceptable salts thereof, and beta-lactam antibiotics. One or more of the macrolide compound as shown in the formula 1, the macrolide compound as shown in the formula 1' and pharmaceutically acceptable salts thereof disclosed by the invention has/have the effects of improving the effects of beta-lactam antibiotics and inhibiting methicillin-resistant staphylococcus aureus (MRSA); the macrolide compound is a novel synergist, is good in in-vitro synergism, is capable of relieving the drug resistance of the methicillin-resistant staphylococcus aureus (MRSA) on beta-lactam antibiotics, and is a medicine with good market development prospect.

Description

technical field [0001] The present invention relates to the application of macrolide compound or its salt and the pharmaceutical composition containing it. Background technique [0002] (a) Prevalence of MRSA and current clinical treatment options [0003] 1. Prevalence characteristics of MRSA [0004] Staphylococcus aureus resistant to methicillin, oxacillin, cefoxitin or mec A gene positive is defined as Methicillin-resistant Staphylococcus aureus, namely MRSA. According to different places of acquisition, MRSA is divided into hospital-acquired MRSA (HA-MRSA) and community-acquired MRSA (CA-MRSA). In the 1960s, HA-MRSA was the leading cause of hospital-acquired infections. [0005] Since MRSA was first isolated in 1961, reports on the outbreak of MRSA infection in the world have increased year by year (Chen Min, Zhou Taoyou. Chen Wenzhao. et al. Clinical and drug resistance of methicillin-resistant Staphylococcus aureus infection. Chinese Journal of Hospital Infection ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7052A61K31/7048A61K31/7056A61P31/04A61K31/431A61K31/43A61K31/546A61K31/545
CPCA61K31/43A61K31/431A61K31/545A61K31/546A61K31/7048A61K31/7052A61K31/7056C07H1/00C07H17/08A61K2300/00
Inventor 沈舜义陈代杰葛涵李继安张志宏李忠磊贺明樊钱永张芸徐屹军任岩松
Owner SHANGHAI INST OF PHARMA IND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap